AbbVie lifts 2026 EPS guidance, closes Apogee deal, posts Skyrizi and Juvmo approvals
Third-quarter revenue rose 10.3 percent as AbbVie raised full-year adjusted EPS guidance and reported positive late-stage data in HS and DLBCL.
SEC filing (6)
3 stories
Third-quarter revenue rose 10.3 percent as AbbVie raised full-year adjusted EPS guidance and reported positive late-stage data in HS and DLBCL.
SEC filing (6)
BioVie sold shares and pre-funded warrants in a registered direct offering alongside a private placement of common warrants, with proceeds earmarked for working capital.
SEC filing